title: Adenoviral transfer of vasoactive intestinal peptide (VIP) gene inhibits rat aortic and pulmonary artery smooth muscle cell proliferation.
abstract: Vasoactive intestinal peptide (VIP), a 28 amino acid peptide, has been shown to inhibit proliferation of vascular smooth muscle cells. In previous studies VIP and VIP analogs have been used to study the effects of the peptide on vascular smooth muscle cell function. In this study an adenovirus encoding the VIP gene was used to investigate the mechanism of the antiproliferative action of VIP in vascular smooth muscle cells. Primary cultures of aortic and pulmonary artery smooth muscle cells from male Sprague-Dawley rats were transfected with varying concentrations of serotype 5 adenovirus encoding human VIP (Ad5CMVhVIP). Transfection efficiency and subsequently VIP gene expression were confirmed by western blot analysis and immunohistochemistry. In this study a decrease in vascular smooth muscle cell proliferation at vector concentrations of 150, 300 and 600MOI (multiplicity of infection) was observed. In addition, there was increased production of cAMP in pulmonary artery and aortic smooth muscle cells transfected with VIP. Treatment of cells with a PKA inhibitor (Rp-8-BrcAMPs) restored proliferation to about 80% of control whereas treatment with the PKG inhibitor Rp-8-BrcGMPs had no significant effect suggesting the involvement of the PKA pathway in the antiproliferative actions of VIP.
authors.affiliation: Department of Pharmacology, Tulane University School of Medicine, 1430 Tulane Ave, New Orleans, LA 70112, USA.
authors.forename: Rose-Claire
authors.initials: RC
authors.lastname: St Hilaire
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Kadowitz
authors.forename: James R
authors.initials: JR
authors.lastname: Jeter
mesh_terms: D015124:8-Bromo Cyclic Adenosine Monophosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D015153:Blotting, Western; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects / Q000235:genetics; D002478:Cells, Cultured; D017868:Cyclic AMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors; D005822:Genetic Vectors; D006976:Hypertension, Pulmonary / Q000188:drug therapy; D007150:Immunohistochemistry; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000166:cytology*; D032389:Myocytes, Smooth Muscle / Q000166:cytology* / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013873:Thionucleotides / Q000494:pharmacology; D014660:Vasoactive Intestinal Peptide / Q000235:genetics / Q000502:physiology*
chemical_list: C105593:8-bromoadenosine-3',5'-cyclic monophosphorothioate; D013873:Thionucleotides; D015124:8-Bromo Cyclic Adenosine Monophosphate; D014660:Vasoactive Intestinal Peptide; D017868:Cyclic AMP-Dependent Protein Kinases
references.citation: Eur J Hum Genet. 2007 Jan;15(1):18-22
references.pmid: 17003842
references.citation: Clin Physiol. 1993 Nov;13(6):677-85
references.pmid: 8119061
references.citation: Proc Natl Acad Sci U S A. 1976 Sep;73(9):3197-200
references.pmid: 787988
references.citation: J Pharmacol Exp Ther. 2005 Oct;315(1):370-81
references.pmid: 15994369
references.citation: Eur Respir J. 2008 Jan;31(1):135-9
references.pmid: 18166594
references.citation: Science. 1970 Sep 18;169(3951):1217-8
references.pmid: 5450698
references.citation: J Appl Physiol (1985). 1985 May;58(5):1723-8
references.pmid: 3997734
references.citation: Regul Pept. 1988 Aug;22(3):267-74
references.pmid: 2902657
references.citation: J Hypertens. 1996 Feb;14(2):209-13
references.pmid: 8728298
references.citation: J Clin Invest. 2003 May;111(9):1339-46
references.pmid: 12727925
references.citation: Mol Cells. 2006 Jun 30;21(3):337-42
references.pmid: 16819295
references.citation: Peptides. 1988 Jul-Aug;9(4):853-8
references.pmid: 2852361
references.citation: Biochem Biophys Res Commun. 2004 Jun 18;319(1):189-92
references.pmid: 15158460
references.citation: Blood Vessels. 1987;24(1-2):45-50
references.pmid: 3567364
references.citation: Pharmacol Ther. 1990;47(3):329-45
references.pmid: 1963221
references.citation: Am J Physiol Lung Cell Mol Physiol. 2005 Jan;288(1):L202-11
references.pmid: 15257984
references.citation: Circulation. 2007 Mar 13;115(10):1260-8
references.pmid: 17309917
references.citation: Cardiovasc Drug Rev. 2001 Fall;19(3):245-62
references.pmid: 11607042
references.citation: Atherosclerosis. 1995 Dec;118 Suppl:S51-6
references.pmid: 8821465
references.citation: In Vitro Cell Dev Biol. 1989 Jun;25(6):511-20
references.pmid: 2661518
references.citation: Am J Physiol. 1986 May;250(5 Pt 2):H755-60
references.pmid: 3010741
references.citation: Regul Pept. 2007 Mar 1;139(1-3):102-8
references.pmid: 17174416
references.citation: Eur Respir J. 1995 Dec;8(12):2129-38
references.pmid: 8666110
references.citation: Am J Physiol. 1995 Jun;268(6 Pt 1):L1047-51
references.pmid: 7541947
references.citation: Arterioscler Thromb Vasc Biol. 2000 Aug;20(8):1873-81
references.pmid: 10938006
references.citation: Regul Pept. 2003 Apr 15;112(1-3):115-20
references.pmid: 12667632
references.citation: Am J Physiol Cell Physiol. 2003 Jan;284(1):C191-9
references.pmid: 12388111
references.citation: Regul Pept. 2002 Oct 15;108(2-3):165-73
references.pmid: 12220741
references.citation: Cardiovasc Surg. 2002 Apr;10(2):138-45
references.pmid: 11888743
references.citation: Circulation. 2000 Feb 29;101(8):923-30
references.pmid: 10694533
references.citation: Science. 1994 Aug 5;265(5173):781-4
references.pmid: 8047883